GlaxoSmithKline Revenue 2006-2018 | GSK

Current and historical revenue for GlaxoSmithKline (GSK) from 2006 to 2018. The sum of all revenue fields included for a company's operating activities. The current revenue for GlaxoSmithKline as of March 31, 2018 is .
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $92.695B $38.892B
GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $337.643B 16.14
Pfizer (PFE) United States $222.220B 13.67
Novartis AG (NVS) Switzerland $190.657B 16.36
Merck (MRK) United States $168.566B 15.06
AbbVie (ABBV) United States $141.089B 14.39
Novo Nordisk (NVO) Denmark $123.252B 20.42
Sanofi (SNY) France $106.218B 13.44
Eli Lilly (LLY) United States $96.028B 19.07
AstraZeneca (AZN) United Kingdom $94.148B 9.86
Bristol-Myers Squibb (BMY) United States $92.695B 18.24